FDA accepts Servier's NDA review for glioma treatment

The US Food and Drug Administration (FDA) has accepted Servier’s NDA filing and priority review for vorasidenib for IDH-mutant diffuse glioma.

Related Keywords

,Susan Pandya ,Servier Cancer Metabolism Global Development Oncology ,European Medicines Agency ,European Commission ,Prescription Drug User Fee Act ,Cancer Metabolism Global Development Oncology ,